ASCO GI 2021 | GARNET: dostarlimab, a PD-1 antibody in advanced solid tumors

Thierry André, MD, Hospital Saint Antoine, Paris, France, discusses the results of the GARNET study, (NCT02715284), an ongoing Phase I trial evaluating dostarlimab, an anti-PD-1 monoclonal antibody in patients with advanced solid tumors. In this interview, Dr Andre outlines how dostarlimab has demonstrated durable antitumor activity in a cohort of mismatch repair-deficient solid tumor patients, the majority of whom had a gastrointestinal malignancy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).